Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01310023 · ClinicalTrials.gov registry record
Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women
A clinical trial, sponsored by Harvard School of Public Health (HSPH).
- Completed
- Registry status
- 5,169
- Enrollment target
NCT01310023 is a clinical trial that has completed, run by Harvard School of Public Health (HSPH). The registered enrollment target is 5,169 participants.
The verdict
NCT01310023 has completed, sponsored by Harvard School of Public Health (HSPH).
- COMPLETED
- Registry status
- 5,169 participants
- Enrollment target
Study Summary
SMARTT will estimate the incidence of conditions and diagnoses potentially related to in utero exposure to antiretroviral therapy and/or exposure in the first two months of life among children born of HIV-infected mothers.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,169 participants |
| Start Date | 2007-03 |
| Est. Completion | 2025-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01310023
The ClinicalTrials.gov registry entry for NCT01310023 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5,169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harvard School of Public Health (HSPH), which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01310023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01310023 about?
NCT01310023 is a clinical study titled "Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women". SMARTT will estimate the incidence of conditions and diagnoses potentially related to in utero exposure to antiretroviral therapy and/or exposure in the first two months of life among children born of HIV-infected mothers.
What is the current status of trial NCT01310023?
This trial is currently completed. The enrollment target is 5,169 participants. The study started on 2007-03. Estimated completion is 2025-05-31.
Who is sponsoring clinical trial NCT01310023?
This trial is sponsored by Harvard School of Public Health (HSPH), which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.